|
|
||||||||
From the Departments of Neurology (W.M.K., R.R., C.H., J.R.M., J.T.K.), Internal Medicine, Physical Medicine and Rehabilitation (V.M., J.L.), Pediatrics, and Statistics (H.N.N.), Ohio State University and Columbus Children's Research Institute, Columbus.
Address correspondence and reprint requests to Dr Kissel, Department of Neurology, Division of Neuromuscular Disease, Ohio State University Medical Center, 1654 Upham Dr., Columbus, OH 43210 kissel.2{at}osu.edu
Objective: To document the effects of long-term daily corticosteroid treatment on a variety of orthopedic outcomes in boys with Duchenne muscular dystrophy.
Methods: We reviewed the charts of 159 boys with genetically confirmed dystrophinopathies followed at the Ohio State University Muscular Dystrophy Clinic between 2000 and 2003. Charts were reviewed for ambulation status, type and duration of steroid treatment (if any), and orthopedic complications including presence and location of long bone fractures, vertebral compression fractures, and the presence and degree of scoliosis.
Results: The cohort consisted of 143 boys (16 boys with Becker dystrophy were excluded); 75 had been treated with steroids for at least 1 year, whereas 68 boys had never been treated or had received only a brief submaximal dose. The mean duration of daily steroid treatment was 8.04 years. Treated boys ambulated independently 3.3 years longer than the untreated group (p < 0.0001) and had a lower prevalence of scoliosis than the untreated group (31 vs 91%; p < 0.0001). The average scoliotic curve was also milder in the treated group (11.6°) compared with the untreated group (33.2°; p < 0.0001). Vertebral compression fractures occurred in 32% of the treated group, whereas no vertebral fractures were discovered in the steroid naive group (p = 0.0012). Long bone fractures were 2.6 times greater in steroid-treated patients.
Conclusions: Although boys with Duchenne muscular dystrophy on long-term corticosteroid treatment have a significantly decreased risk of scoliosis and an extension of more than 3 years' independent ambulation, they are at increased risk of vertebral and lower limb fractures compared with untreated boys.
Supported by the General Clinical Research Center at the Ohio State University and grant MO1-RR00034 from the National Center of Research Resources of NIH.
Disclosure: The authors report no conflicts of interest.
Received September 6, 2006. Accepted in final form January 12, 2007.
This article has been cited by other articles:
![]() |
A Y Manzur, M Kinali, and F Muntoni Update on the management of Duchenne muscular dystrophy Arch. Dis. Child., November 1, 2008; 93(11): 986 - 990. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Birnkrant, H. B. Panitch, J. O. Benditt, L. J. Boitano, E. R. Carter, V. A. Cwik, J. D. Finder, S. T. Iannaccone, L. E. Jacobson, G. L. Kohn, et al. American College of Chest Physicians Consensus Statement on the Respiratory and Related Management of Patients With Duchenne Muscular Dystrophy Undergoing Anesthesia or Sedation Chest, December 1, 2007; 132(6): 1977 - 1986. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |